Results 201 to 210 of about 11,232 (271)

A sustainable business ecosystem: a case study demonstrating biochar's potential

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract The need for renewable, climate‐friendly resources has become urgent as legislators worldwide have sought to find ways to cut emissions while ensuring resource security for consumers. The use of biochar could help to achieve these goals. This study examines the current state of commercial biochar production and the maturity of the related ...
Kivijakola Juuso   +4 more
wiley   +1 more source

Combined effect of increasing the post‐reformer temperature and adding red mud as a secondary catalyst in the thermocatalytic reforming of digestate

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract This work studies the combined effect of increasing the post‐reformer temperature and introducing red mud as a support catalyst in the thermocatalytic reforming (TCR®) of digestate. The TCR® method, developed by the Fraunhofer Institute for Environmental, Safety and Energy Technology UMSICHT (abbreviated as Fraunhofer UMSICHT), is an extension
Hillary Onyishi   +4 more
wiley   +1 more source

Chlorella vulgaris biorefineries: sustainable biofuels and high‐value carbon capture

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Global reliance on fossil fuels has created urgent economic and environmental challenges, yet large‐scale use of algal biomass remains limited by production costs. Industrial scaling is constrained by inefficient harvesting and the technical challenges of processing recalcitrant cell walls.
Sandyelle Ferreira Alcântara Araújo   +13 more
wiley   +1 more source

Comparative field‐scale assessment of TLUD and Kon‐Tiki biochar systems: agronomic performance and net CO2e‐based techno‐economics

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Post‐harvest agricultural residues in Latin America are commonly underutilized, leading to greenhouse gas emissions and lost opportunities for bio‐based value creation. This study tests the hypothesis that decentralized, farmer‐scale pyrolysis technologies can deliver comparable agronomic benefits while exhibiting distinct techno‐economic and ...
Juan F. Saldarriaga   +7 more
wiley   +1 more source

Enzymatic synthesis of acylglycerides from agroindustrial residues: process design and simplified techno‐economic assessment

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract This study developed an enzymatic process to add value to palm oil fatty acid distillate (PFAD) and glycerol, resulting in the production of monoacylglycerides (MAG) and diacylglycerides (DAG). The biocatalyst loading (Novozym 435) and molar ratio of reagents were evaluated to obtain a suitable reaction condition in terms of space–time yield ...
Ronaldo Rodrigues de Sousa   +4 more
wiley   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden   +3 more
wiley   +1 more source

Therapeutic drug monitoring of antimicrobials in a paediatric setting: A retrospective single‐centre study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga   +20 more
wiley   +1 more source

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy